Li et al. demonstrated that decreasing FASN activity could improve T cell anti-tumor immunity while partially restoring the antigen-presenting ability of tumor-infiltrating dendritic cells, thereby contributing to ovarian cancer therapy [7]. Here, FASN is linked to ovarian carcinoma.